Rob Dekker joins TargED as Vice President CMC

We are pleased to welcome Rob Dekker as Vice President CMC (Chemistry, Manufacturing and Controls).

Rob brings nearly three decades of experience in biopharmaceutical development and manufacturing, with a strong track record of advancing complex biologics and vaccines from early clinical development through regulatory submission and commercialization.

As we continue advancing TGD001, our first-in-class targeted thrombolytic, Rob will play a key role in strengthening our CMC strategy and manufacturing capabilities as we prepare for later-stage clinical development.